Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolic disorders in adult patients at risk of clot formation. GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep is a low molecular weight heparin used in the management of venous thromboembolism and related surgical prophylaxis. - Deep vein thrombosis: prevention and treatment of clot formation in the deep veins of the lower extremities. - Pulmonary embolism: prevention and treatment of embolic obstruction in the pulmonary arteries. - Surgical thromboprophylaxis: reduction of postoperative thromboembolic events in patients undergoing major surgery.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the subcutaneous injection site. - Bruising or hematoma: localized bleeding under the skin. - Minor bleeding: such as gum or nosebleeds. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Severe bleeding: life‑threatening hemorrhage in any organ system. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated drop in platelet count with paradoxical clot risk. - Spinal or epidural hematoma: bleeding in the spinal canal after neuraxial procedures. - Allergic reaction: urticaria, angioedema, or anaphylaxis. - Elevated liver enzymes: abnormal hepatic function tests.

Use of Innohep requires careful assessment of patient‑specific risk factors. - Renal impairment: adjust dosing and monitor anti‑Xa levels in patients with reduced kidney function. - Hepatic disease: consider increased bleeding risk and monitor liver function. - Concomitant anticoagulants: avoid or closely monitor when used with other anticoagulant or antiplatelet agents. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Elderly patients: increased susceptibility to bleeding; monitor closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium may interact with several drug classes, affecting bleeding risk or anticoagulant efficacy.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct oral anticoagulants): additive anticoagulant effect leading to severe bleeding. - Thrombolytic agents (e.g., alteplase): heightened risk of hemorrhage. - Neuraxial anesthesia or spinal puncture: increased chance of spinal/epidural hematoma.

Moderate Interactions (Monitor Closely): - Antiplatelet drugs (e.g., aspirin, clopidogrel): may modestly increase bleeding tendency. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may enhance mucosal bleeding.